Home/Pipeline/Target 4 Program

Target 4 Program

Obesity and Cardiometabolic Disease

DiscoveryActive

Key Facts

Indication

Obesity and Cardiometabolic Disease

Phase

Discovery

Status

Active

Company

iBio

About iBio

iBio is focused on creating transformative antibody therapies for obesity and cardiometabolic disorders by integrating artificial intelligence with experimental biology. Its platform enables the discovery of antibodies against challenging targets like GPCRs, with a pipeline featuring candidates designed to preserve muscle mass, target fat selectively, and enable less frequent dosing. The company is advancing multiple programs from discovery through IND-enabling stages, positioning itself in the rapidly expanding obesity therapeutics market.

View full company profile

Therapeutic Areas

Obesity Cardiometabolic Disease

Other Obesity and Cardiometabolic Disease Drugs

Drug	Company	Phase	Status
IBIO-610	iBio	IND-Enabling	Active
Myostatin x Activin A Bispecific	iBio	Optimization	Active
IBIO-600	iBio	IND-Enabling	Active
Amylin Antibody	iBio	Optimization	Active